Agios Pharmaceuticals (AGIO) Cash & Equivalents (2012 - 2026)

Agios Pharmaceuticals' Cash & Equivalents history runs 15 years deep, the most recent figure standing at $113.6 million for Q1 2026.

• Quarterly Cash & Equivalents rose 43.86% year-over-year to $113.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $113.6 million (up 43.86% YoY) and the FY2025 annual result came in at $89.1 million, up 16.9% from the prior year.
• Cash & Equivalents was $113.6 million for Q1 2026 at Agios Pharmaceuticals, up from $89.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $253.7 million in Q3 2024 and bottomed at $64.3 million in Q3 2023.
• A 5-year average of $103.5 million and a median of $88.5 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 95.76% — and 2024, when it soared 294.4%.
• Agios Pharmaceuticals' Cash & Equivalents stood at $139.3 million in 2022, then plunged by 36.66% to $88.2 million in 2023, then retreated by 13.56% to $76.2 million in 2024, then increased by 16.9% to $89.1 million in 2025, then grew by 27.45% to $113.6 million in 2026.
• Business Quant data shows AGIO's Cash & Equivalents at $113.6 million in Q1 2026, $89.1 million in Q4 2025, and $92.7 million in Q3 2025.